ReviewSeminars in interventional radiology2015
Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts.
Review in Seminars in interventional radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Utility of Yttrium-90 Radioembolization for the Treatment of Fibrolamellar Hepatocellular Carcinoma: A Tertiary Cancer Center Experience.Journal of hepatocellular carcinoma · 2026Article
- Musculoskeletal abscopal effect: a review of the important imaging findings and their clinical relevance.Skeletal radiology · 2025Review
- Augmenting the Future Liver Remnant Prior to Major Hepatectomy: A Review of Options on the Menu.Annals of surgical oncology · 2025Review
- Safety and Efficacy of Primary Stent Placement for Hepatic Artery Kinks in Liver Transplant Recipients.Cardiovascular and interventional radiology · 2025Article
- Yttrium-Enriched Phosphate Glass-Ceramic Microspheres for Bone Cancer Radiotherapy Treatment.ACS omega · 2024Article
- Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.Journal of clinical and translational research · 2021Review
- PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.European journal of nuclear medicine and molecular imaging · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a lethal tumor, claiming over half a million lives per year. Treatment of HCC is commonly performed without curative intent, and palliative options dominate, including catheter-based therapies, namely, transarterial chemoembolization and yttrium-90 ((90)Y) radioembolization. This review will showcase the performance of (90)Y radioembolization for the treatment of HCC, focusing on recent seminal data and technical advances. In particular, novel radioembolization treatment concepts are discussed and compared with conventional HCC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.